Table 5.

Cox regression sensitivity analysis of patients receiving rituximab after documented EBV reactivation

Multivariable Cox regression analysis
VariableTime-independent analysesTime-dependent analyses
HR95% CIP valueHR95% CIP value
Preemptive rituximab 0.25 0.06-1.06 .060 0.43 0.10-1.80 .2 
Log-transformed peak EBV viral load (IU/mL) 1.26 1.15-1.38 <.001 1.25 1.15-1.37 <.001 
Duration of EBV DNAemia (mo) 0.99 0.99-1.00 .078 0.99 0.99-1.00 .053 
Time from SOT to EBV reactivation (mo) 0.99 0.98-1.00 <.001 0.99 0.98-0.99 <.001 
D/R serostatus∗  - - - - - - 
Intermediate risk - - - - - - 
High risk 3.08 1.79-5.32 <.001 3.15 1.84, 5.39 <.001 
Low risk 1.64 0.48-5.61 .4 1.71 0.50, 5.85 .4 
High-risk organ†  3.83 2.09-7.02 <.001 3.95 2.16, 7.23 <.001 
Age of <18 years at transplant 1.14 0.65-2.01 .7 1.11 0.63, 1.95 .7 
Multivariable Cox regression analysis
VariableTime-independent analysesTime-dependent analyses
HR95% CIP valueHR95% CIP value
Preemptive rituximab 0.25 0.06-1.06 .060 0.43 0.10-1.80 .2 
Log-transformed peak EBV viral load (IU/mL) 1.26 1.15-1.38 <.001 1.25 1.15-1.37 <.001 
Duration of EBV DNAemia (mo) 0.99 0.99-1.00 .078 0.99 0.99-1.00 .053 
Time from SOT to EBV reactivation (mo) 0.99 0.98-1.00 <.001 0.99 0.98-0.99 <.001 
D/R serostatus∗  - - - - - - 
Intermediate risk - - - - - - 
High risk 3.08 1.79-5.32 <.001 3.15 1.84, 5.39 <.001 
Low risk 1.64 0.48-5.61 .4 1.71 0.50, 5.85 .4 
High-risk organ†  3.83 2.09-7.02 <.001 3.95 2.16, 7.23 <.001 
Age of <18 years at transplant 1.14 0.65-2.01 .7 1.11 0.63, 1.95 .7 
∗

As compared with intermediate-risk serostatus. High-risk serostatus, D+/R−; intermediate-risk serostatus, D−/R+, D+/R+; low-risk serostatus, D−/R−.

†

High-risk organ transplant types: lung and multivisceral/intestinal transplants.

View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal